A scientist works in a laboratory at the Novavax facility in Gaithersburg, MD (Jon Cherry/Bloomberg via Getty Images)

FDA ad­vi­sors vote 21-0, with one ab­sten­tion, to au­tho­rize No­vavax’s Covid-19 vac­cine to be the fourth US op­tion

A pan­el of FDA’s out­side ex­perts rec­om­mend­ed 21 to 0, with one mem­ber ab­stain­ing, that the agency give emer­gency use au­tho­riza­tion for No­vavax’s two-dose Covid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA